66 results about "Aqueous humor" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

The utility model discloses an ophthalmology radiofrequency ablation training model which is used for assisting an ophthalmology radiofrequency ablation electrode used in cooperation with an ophthalmology radiofrequency ablation instrument in simulated puncture training on eyeballs, and the ophthalmology radiofrequency ablation electrode is provided with an electrode needle and an impedance detection unit electrically connected with the electrode needle. The ophthalmology radiofrequency ablation training model comprises a base and an eyeball model, wherein the eyeball model comprises a simulated sclera structure, a simulated ciliary body structure and simulated aqueous humor; the simulated sclera structure and the simulated ciliary body structure are made of conductive materials, the simulated sclera structure has a first impedance range, the simulated ciliary body structure has a second impedance range, and the simulated aqueous humor has a third impedance range; when the needle point of the electrode needle pierces into the simulated sclera structure, the simulated ciliary body structure and the simulated aqueous humor, the impedance detection unit can feed back an impedance value, and an operator can judge whether the piercing position and the piercing depth meet requirements or not according to the impedance value.

The invention provides an ophthalmology minimally invasive drainage device, and relates to the technical field of medical instruments. The device comprises a drainage tube, a dispersion tube and a release tube which are fixed into a whole, the longitudinal sections of the drainage tube, the dispersion tube and the release tube are flat, and a liquid inlet assembly used for liquid inlet is arranged at the left end of the drainage tube; the upper part of the drainage tube is provided with a fixing assembly for limiting an operation line; the dispersing pipe is fixedly connected with a fixing lug; the releasing pipe is in a circular arc shape, a pressure stabilizing film is arranged at the right end of the releasing pipe, and a pressure stabilizing opening is formed between the pressure stabilizing film and the releasing pipe. Through the arranged fixing assembly, the operation line can be limited, the stability of the drainage tube is guaranteed, the operation quality is improved, and operation complications are reduced; through the arrangement of the pressure stabilizing film and the pressure stabilizing opening, the size of the pressure stabilizing opening can be changed by utilizing the characteristic that the pressure stabilizing film deforms under pressure, the stable pressure of aqueous humor in the anterior chamber is ensured, and treatment of glaucoma is facilitated.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The non-intrusive measuring system for the glucose concentration of the aqueous humor of the eyes comprises a linear polarization collimation light source which emits an incident polarized light beam along an advancing optical axis at a linear polarization starting angle, penetrates through a cornea, enters the aqueous humor and generates an emergent polarized light beam; the linear polarization starting angle of the incident polarized light beam is defined as a 45-degree rotation angle along the advancing direction of the advancing optical axis; the first polarization beam splitter is used for splitting the emergent polarized light beam into two emergent polarized light beam components with orthogonal polarization directions, and the two emergent polarized light beam components are respectively polarized at 0-degree and 90-degree rotation angles along respective advancing optical axis directions; the two light sensors are used for respectively measuring the light intensity of the two emergent polarized light beam components; an arithmetic processor for subtracting the light intensity to obtain a Schtort vector S1 component related to the amount of rotation of the polarization angle; and normalizing the S1 component by adding the light intensities of the emitted polarized light beam components as a standard value.

A shunt for treating glaucoma that includes a silicone rubber duct for diverting aqueous humor from a chamber of a patient's eye and a fixation body frictionally located on the duct in an arrangement permitting sliding displacement of the fixation body, for fixing and sealing the duct within scleral tissue surrounding the eye. The duct has a rigid proximal portion having a proximal end and a deformable distal portion locatable in the scleral channel and having a distal end. The distal portion is severable, allowing a surgeon to cut the distal portion to a desired length corresponding to the anatomical dimensions of the patient's eye and a required bleb position. The proximal portion has a capillary lumen having a diameter which is smaller than the diameter of a lumen of the distal portion, thereby reducing a flow rate of aqueous humor along the capillary lumen.

The utility model relates to a glaucoma drainage tube with double drainage discs, which belongs to the technical field of medical artificial implants and comprises a drainage tube body, a drainage mechanism is arranged on the right side of the drainage tube body and comprises a fixing structure fixedly mounted on the outer side of the drainage tube, and the double-layer drainage discs are fixedly mounted on the right side of the fixing structure. The glaucoma drainage tube with the double drainage discs can be easily implanted into an anterior chamber corner during an operation, can be accurately butted with an aqueous fluid generation source, ensures that aqueous fluid flows in without hindrance, lays a solid foundation for subsequent drainage, can be tightly attached to a sclera by virtue of the characteristics of the fixing structure, greatly reduces the displacement risk of an implant, ensures stable operation of a whole drainage system, and has a good application prospect. The upper drainage disc and the lower drainage disc cooperatively operate, the conjunctival sac is accurately opened, a stable filtering bubble is formed, the drainage groove matched with the drainage tube body in the drainage tube forms a smooth aqueous humor channel, aqueous humor drainage is accelerated, the supporting structure efficiently promotes aqueous humor diffusion between the two layers of drainage discs, and the drainage efficiency is comprehensively optimized.

The present invention relates to an ophthalmic ultrasonic emulsification sleeve for confirming intraocular and extraocular penetration and perfusion, which allows determining whether aqueous humor communication between the inside and outside of the eye is smooth through a microtube implanted in the eye during glaucoma tube surgery. The sleeve is characterized by having a rigid branch tube made of a material harder than a sleeve made of a soft material, provided in a perfusion port that allows the injection of a balance salt solution into the eye, and with the branch tube connected to the perfusion port, the tip of the branch tube protrudes further than the tip of the Paco tip, and the end of the microtube inside the eye is connected to the tip of the branch tube, so that the establishment of aqueous humor communication of the microtube can be quickly and accurately and sensorially confirmed based on the pattern of pressure change in the conjunctival area and surrounding blood flow change that occurs when the balance salt solution leaks out of the eye.

The invention provides a biomarker for detecting anti-VEGF treatment typing of diabetic macular edema and extracellular vesicle protein for judging the severity of diabetic retinopathy, and the protein with remarkable expression difference is screened out by analyzing the expression difference of the extracellular vesicle protein in aqueous humor of a patient. Wherein C5 and CD34 can be used as biomarkers of DME anti-VEGF treatment typing, C5 can be used for judging the severity of diabetic retinopathy (DR), important guidance is provided for DME or DR personalized treatment, and the C5 and CD34 have wide clinical application prospects.

The present disclosure relates to an eye disease implant device, and an eye disease implant device according to an embodiment of the present disclosure includes a tube including a hollow portion through which aqueous humor is drained, wherein one or more wings extending in a direction different from a longitudinal direction of the tube are formed on a portion of an outer surface of the tube. Also, the eye disease implant device may further include a body including a receiving space into which an end of the tube is inserted. In this case, the end of the tube may be inserted into the receiving space to be coupled to the body, or detached from the receiving space to be separated from the body.

The present disclosure pertains to the phakic refractive lenses such as toric lenses, an advanced posterior chamber floating phakic refractive lens (PRL) designed for the correction of severe refractive errors, including myopia, hyperopia, and astigmatism. This innovative lens can reduce or minimize complications commonly associated with traditional phakic intraocular lenses, such as intraocular pressure elevation, cataract formation, and iris pigment dispersion. The phakic refractive lenses such as the toric lenses described herein feature a buoyant, flexible structure with a central aperture to facilitate aqueous humor flow, creating a natural centering force that stabilizes the lens within the pupillary space.

The invention discloses a glaucoma internal aqueous humor drainage support and relates to the technical field of medical instruments.The drainage support comprises a support body, a drainage piece and an adjusting assembly, the first end of the support body is a blind end, the second end of the support body is provided with an opening, a drainage channel communicated with the opening is formed in the support body in a penetrating mode, and the first end of the support body is provided with an open window; the drainage part is arranged in the support body and located below the window, an installation groove is formed in the drainage part, a through drainage hole is formed in the installation groove and communicated with the drainage channel and the window, and the adjusting assembly is arranged on the installation groove and used for adjusting the opening area of the drainage hole. The size of the opening area of the drainage hole is adjusted through the adjusting assembly, the opening area of the drainage hole can be adjusted according to the eye pressure, and the adjusting accuracy of the eye pressure is guaranteed.

To provide apparatus and methods for treating glaucoma in a patient's eye (25).SOLUTION: A treatment laser beam is directed at the trabecular meshwork of the patient's eye to initiate reactions that promote improved drainage of aqueous humor fluid.SELECTED DRAWING: Figure 3a

An aqueous micro shunt for treating dry eye syndrome comprises an axially oriented shaft, for insertion through a scleral wall portion of an eye and into an anterior chamber of the eye, and having an open distal end adapted to be fluidically connected to aqueous humor contained within the anterior chamber of the eye. First and second axially oriented lumens are defined within the axially oriented shaft, and a plate is fixedly mounted at a predetermined angle upon a proximal end of the axially oriented shaft. A slot is defined within the plate so as to be fluidically connected to the second axially oriented lumen defined within said axially oriented shaft such that aqueous fluid can flow from the anterior chamber of the eye, through the first and second lumens defined within the axially elongated shaft, and outwardly through the slot defined within the plate so as to flow over an ocular surface portion of the eye and thereby treat dry eye syndrome.

Systems and devices for applying radiation to a target area, for example for maintaining functioning drainage blebs or functioning drainage holes in the eye, e.g., to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The systems and devices of the present invention provide for the application of beta radiation to the target area, wherein the beta radiation can function to inhibit or reduce the inflammation and / or fibrogenesis that may occur after insertion of an implant into the eye or introduction of a hole for the purpose of draining aqueous humor to maintain a healthy intraocular pressure. By reducing inflammation and / or fibrogenesis, the implant, the hole, the blebs, or other related structures or tissues can remain functioning appropriately.

The invention relates to the technical field of pharmaceutical preparations, in particular to Janus kinase inhibitor in-situ gel eye drops and application thereof. The invention provides a Janus kinase inhibitor in-situ gel eye drop. The liquid preparation comprises a Janus kinase inhibitor with the concentration of 30 to 500 [mu] g / mL and gellan gum with the concentration of 4 to 5.5 mg / mL. The gellan gum ion type in-situ gel eye drops have the dual characteristics of quick release and continuous release, the drug concentration in aqueous humor can be kept at a high level in a long time, the highest drug concentration and the accumulated drug amount are greatly improved, the bioavailability is increased, the drug use frequency can be reduced, the patient compliance is improved, and the preparation method is simple and convenient. Compared with an existing oral preparation, the pharmaceutical composition can better exert the treatment effect.

To provide a glaucoma treatment device.SOLUTION: A glaucoma treatment device includes a plurality of microporous layers arranged together so as to form a microporous body configured to facilitate an evacuation of fluid from a fluid-filled body cavity and reabsorption of drained aqueous humor by the body through tissue surrounding the glaucoma treatment device. In some examples, the glaucoma treatment device includes one or more portions configured to resist cellular internal growth and one or more portions configured to allow the cellular internal growth. Especially, the outside thereof may comprise or be defined by one or more membranes, where the membranes are porous or otherwise permeable to the fluid of the fluid-filled body cavity.SELECTED DRAWING: Figure 1

A bypass device is implanted into a body tissue via a minimally invasive surgery to provide fluid channels through the body tissue. The bypass device includes a base portion having opposite first and second ends, and flexed tines attached to the base portion configured in a flexed position relative to the base portion. The base portion includes flow spaces present from where the flexed tines are flexed relative to the base portion, the flow spaces permitting fluid flow through the bypass device. The bypass device further includes an anchor tine located adjacent to the second end of the base portion that aids in securing the bypass device in place after implantation. The bypass device may be implanted in the eye using a MIGS procedure for the treatment of glaucoma, whereby aqueous humor is permitted to flow through the flow spaces of the bypass device.

The present application provides an aqueous humor drainage device, which comprises two drainage tubes arranged in parallel along the radial direction and a support body embracing the two drainage tubes, the drainage tubes are curved in an arc shape along the axial direction to adapt to the physiological curvature of the sclera, the support body has a bottom supported on the inner concave surface of the arc-shaped curve of the drainage tubes and embracing parts extending from the two sides of the bottom along the outer side walls of the two drainage tubes away from each other. The present application adopts two polymer thin tubes with hollow channels arranged in parallel as the drainage tubes and the support body structure design embracing the drainage tubes, which makes full use of the flexibility of the polymer tubes and the toughness of the support body, improves the compatibility of the surrounding tissues and the device, and can continuously maintain good drainage effect.

Glaucoma shunts including an elongate body with an outer surface and an inner surface, the elongate body comprising an inner wall that defines a lumen spanning a length of the elongate body are disclosed herein. Also disclosed are methods of decreasing intraocular pressure in an eye, the method comprising inserting at least a portion of a glaucoma shunt into an anterior chamber of the eye, and draining aqueous humour from the anterior chamber through the lumen.

The application provides an eye preparation for preventing and treating cataract by eye drop, which is composed of an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient; the active substance for treating eye diseases is oxidized cholestanol, including lanosterol or 25-hydroxycholestanol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent and a solvent; the content of the oxidized cholestanol in the preparation is 0.01-5 mg / mL; the mass ratio of the surfactant, the tackifier, the cosolvent and the oxidized cholestanol is (1-300):(1-100):(100-3000):1, and the rest is the solvent. After the eye drop of the preparation, the active substance can be selectively enriched in the lens of experimental animals, so that the effect of treating cataract can be accurately exerted, and the active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding the toxic and side effects on other eye tissues and the whole body. The application solves the technical problem which people in the field of ophthalmic drug delivery have been eager to solve but have failed to obtain success, and has a very high clinical application value and social value.

The utility model discloses a comfortable wearing type sclera lens, which comprises an optical area which is positioned in the center of the sclera lens and is used for correcting vision, a transition area which surrounds the periphery of the optical area and a landing area which surrounds the periphery of the transition area, the optical area and the transition area are of an integrally formed structure, and the transition area and the landing area are of a split type structure. The optical area and the transition area are hard areas, the landing area is a soft area, at least three clamping holes are evenly distributed in the transition area in the circumferential direction of the transition area, the landing area is correspondingly provided with connecting protrusions matched with the clamping holes in shape, the transition area and the landing area are connected in a clamped mode through the clamping holes and the connecting protrusions, and the landing area is further provided with a plurality of cone-like micro holes with the hole diameters large inside and small outside. The landing area is well matched with the sclera and softly lands on the sclera, the pressure borne by the sclera can be reduced, the micropore design of the landing area can not only promote circulation of internal and external aqueous humor of the sclera lens and provide enough oxygen for the cornea, but also promote discharge of bubbles and metabolites below the lens, and the wearing comfort of the eyes of a patient is improved.

The invention relates to the technical field of targeted drug screening, in particular to a targeted drug screening system of a blue-eyelash syndrome anterior aqueous humovirus host interacting protein. According to the technical scheme, multi-dimensional heterogeneity data of a patient suffering from the blue-eyelash syndrome is obtained through an acquisition terminal, and the multi-dimensional heterogeneity data is vectorized through a processing terminal so as to obtain a first vector of clinical performance characteristics of each patient and a second vector of interaction protein performance characteristics; according to the first vector and the second vector, obtaining a variable coefficient set representing relative differences of various characteristics; obtaining the matching degree and symptom relieving potential of the current patient on different targeted drugs according to the current patient on the drug and clinical characteristic standard value, the variable coefficient set and the affinity and action effect of the different targeted drugs; and outputting a drug screening result of the current patient according to the matching degree and the symptom relieving potential of each targeted drug. According to the technical scheme, each patient can accurately screen out the medicine suitable for treating the blue eyelash syndrome based on the multi-dimensional heterogeneity data.

A device and method for disrupting ocular tissue to treat glaucoma and other conditions. The distal portion, sized and configured for intraocular insertion, includes an elongated flexible shaft, a distal guide member, and a tissue disruption portion coupled to the shaft proximal to the guide member. The tissue disruption portion includes protrusions and a blunt tissue-engaging surface lacking any cutting elements. The distal guide member is configured to be inserted through the trabecular meshwork and into a portion of Schlemm's canal. As the distal guide member advances along Schlemm's canal, the tissue-engaging surface of the protrusions bluntly lacerates the trabecular meshwork tissue, removing a portion of the inner wall of Schlemm's canal.